50 Years of progress in the systemic therapy of non-small cell lung cancer

Heather Wakelee, Karen Kelly, Martin J. Edelman

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Non-small cell lung cancer constitutes 85% to 90% of lung cancer and is the most common cause of cancer death. Over the past 50 years, substantial progress has been made in all aspects of lung cancer including screening, diagnostic evaluation, surgery, radiation therapy, and chemotherapy. This review focuses on the advances in systemic therapy during this half century.

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Early Detection of Cancer
Cause of Death
Radiotherapy
Drug Therapy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{7bd7940b03e7435a86541ab352da7e2f,
title = "50 Years of progress in the systemic therapy of non-small cell lung cancer",
abstract = "Non-small cell lung cancer constitutes 85{\%} to 90{\%} of lung cancer and is the most common cause of cancer death. Over the past 50 years, substantial progress has been made in all aspects of lung cancer including screening, diagnostic evaluation, surgery, radiation therapy, and chemotherapy. This review focuses on the advances in systemic therapy during this half century.",
author = "Heather Wakelee and Karen Kelly and Edelman, {Martin J.}",
year = "2014",
doi = "10.14694/EdBook_AM.2014.34.177",
language = "English (US)",
pages = "177--189",
journal = "American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting",
issn = "1548-8756",
publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - 50 Years of progress in the systemic therapy of non-small cell lung cancer

AU - Wakelee, Heather

AU - Kelly, Karen

AU - Edelman, Martin J.

PY - 2014

Y1 - 2014

N2 - Non-small cell lung cancer constitutes 85% to 90% of lung cancer and is the most common cause of cancer death. Over the past 50 years, substantial progress has been made in all aspects of lung cancer including screening, diagnostic evaluation, surgery, radiation therapy, and chemotherapy. This review focuses on the advances in systemic therapy during this half century.

AB - Non-small cell lung cancer constitutes 85% to 90% of lung cancer and is the most common cause of cancer death. Over the past 50 years, substantial progress has been made in all aspects of lung cancer including screening, diagnostic evaluation, surgery, radiation therapy, and chemotherapy. This review focuses on the advances in systemic therapy during this half century.

UR - http://www.scopus.com/inward/record.url?scp=85003049018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003049018&partnerID=8YFLogxK

U2 - 10.14694/EdBook_AM.2014.34.177

DO - 10.14694/EdBook_AM.2014.34.177

M3 - Article

C2 - 24857075

AN - SCOPUS:85003049018

SP - 177

EP - 189

JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

SN - 1548-8756

ER -